Company Overview

Xencor, Inc. is a publicly traded clinical-stage biotechnology company focused on the discovery and development of engineered monoclonal antibodies and cytokines for the treatment of cancer and immune-related diseases. The company operates within the biopharmaceutical and biotechnology industries, with core expertise in protein engineering technologies that enhance the efficacy, safety, and half-life of antibody-based therapeutics.

Xencor’s primary value is derived from its proprietary XmAb® antibody engineering platform, which is used both for internal drug candidates and for partnered programs with large pharmaceutical companies. The company was founded in 1997 and has evolved from a technology-licensing model into a diversified pipeline developer with multiple internally developed clinical-stage programs, while continuing to generate revenue through collaborations, milestones, and royalties.

Business Operations

Xencor operates as a single reportable business focused on antibody and cytokine engineering, with activities spanning research, preclinical development, and clinical trials. Revenue is primarily generated through collaboration agreements, including upfront payments, research funding, milestone payments, and royalties tied to partnered products that incorporate Xencor’s technology.

The company controls proprietary protein engineering technologies, including Fc domain modifications that enhance immune activation, stability, and pharmacokinetics. Xencor conducts most research and development internally in the United States, while clinical trials are executed domestically and internationally through contract research organizations. The company has no separately reported operating subsidiaries based on publicly available disclosures; data inconclusive based on available public sources.

Strategic Position & Investments

Xencor’s strategy centers on advancing wholly owned clinical programs while selectively partnering assets to manage risk and fund innovation. Growth initiatives emphasize bispecific antibodies, engineered cytokines, and immune-oncology candidates designed to improve therapeutic index compared to first-generation biologics.

The company maintains multiple strategic collaborations with large pharmaceutical companies, including Amgen, Novartis, and Alexion Pharmaceuticals (AstraZeneca Rare Disease), among others, which leverage the XmAb platform across oncology and autoimmune indications. Xencor has not pursued large-scale acquisitions as a primary growth strategy; instead, it focuses on internal R&D investment and partnership-driven expansion. Where specific investment terms differ across disclosures, data inconclusive based on available public sources.

Geographic Footprint

Xencor is headquartered in Monrovia, California, and its primary research and administrative operations are based in the United States. The company’s workforce and laboratory infrastructure are concentrated domestically, reflecting its research-intensive operating model.

Internationally, Xencor’s presence is primarily through global clinical trials and collaborations with multinational pharmaceutical partners. These partnerships extend the company’s operational and commercial reach into Europe, Asia, and other regions without requiring a large direct international footprint.

Leadership & Governance

Xencor was founded by Bassil I. Dahiyat, who has played a central role in shaping the company’s technology-driven strategy and long-term vision. The leadership team emphasizes disciplined capital allocation, scientific rigor, and a balance between internal pipeline development and external partnerships.

Key executives include:

• Bassil I. Dahiyat – President and Chief Executive Officer
• Nancy Valente – Chief Financial Officer
• John Desjarlais – Chief Scientific Officer

The company is governed by a board of directors with experience across biotechnology, pharmaceuticals, and capital markets, aligning governance practices with publicly traded life sciences peers.